Most research organizations are now engaged with external collaborators to execute their drug discovery projects. However, working with external partners creates additional challenges that must be addressed to ensure that projects are successful.
In this webinar you will learn how the Dotmatics Cloud solution provides a complete informatics environment design to optimize external scientific collaboration. It enables scientific data exchange, real-time project communication, a collaboration environment, request management and project monitoring. The solution is flexible enough to address all types of collaboration from simple fee-for-service synthesis and assay arrangements to large multisite joint IP discovery projects.
Register for this webinar to hear how Convergence and Sygnature are using the Dotmatics Cloud solution to facilitate their internal and external research projects.
Presented by
Dr Robert Brown,
VP Global Informatics
Rob Brown is VP of Global Informatics at Dotmatics. He previously spent 10 years at Biovia/ Accelrys where is he was responsible for the product marketing teams for cheminformatics, and bioinformatics for the Life Sciences industries. Prior to its acquisition by Accelrys, Rob was the Director of Product Marketing for Pipeline Pilot at Scitegic. Prior to this he also held positions at MSI and Abbott Laboratories. Rob received his PhD in Cheminformatics from the University of Sheffield, UK under the direction of Prof Peter Willett.
Dr. Ting Qin,
Senior scientist
Ting has over 10 years of experience in molecular modelling and informatics. After obtaining a bachelor degree in chemistry and a master degree in computer science in China, he moved to the UK and completed his PhD in molecular modelling at the University of Oxford. After several years of post-doctoral experience, he joined Sygnature Discovery in 2013 as a computational chemist and cheminformatician. Currently Ting is responsible for delivering and customising Dotmatics components for the company, such as inventory systems and chemistry ELN. He also provides internal cheminformatics training and support for Sygnature's scientists on various research projects.
Dr David Witty,
Director of Chemistry and Operations Convergence Pharmaceuticals
David Witty has worked as a Medicinal Chemist for more than 20 years in several large research organisations, including Reckitts, SmithKline Beecham and GSK. He has led enzyme, receptor and ion channels drug discovery programmes across a range of therapeutic areas, from anti-infectives to neuroscience. His interests include training, best practise, instrument automation and effective use of computational techniques in drug discovery; he helped design and deploy an electronic notebook across research in GSK. In 2010 he was a founding member of Convergence Pharmaceuticals Ltd., now a wholly owned subsidiary of Biogen Inc., and in 2015 enabled the spin-out of Calchan Ltd as a new research organisation. He led the integration of Dotmatics software into the operating model for drug discovery at Convergence, where he is presently Chemistry Director and Operations Manager.
